Skip to main content
Top
Published in: Pediatric Drugs 6/2010

01-12-2010 | Original Research Article

Ondansetron Dosing in Pediatric Gastroenteritis

A Prospective Cohort, Dose-Response Study

Authors: Stephen B. Freedman, Elizabeth C. Powell, Alejandro A. Nava-Ocampo, Dr Yaron Finkelstein

Published in: Pediatric Drugs | Issue 6/2010

Login to get access

Abstract

Background

Ondansetron is increasingly used to prevent emesis in children with acute gastroenteritis; however, the optimal dose is unknown.

Objective

To determine if higher doses of oral ondansetron are associated with greater efficacy or side effects.

Methods

We analyzed data from a prospective clinical trial performed between January 2004 and April 2005. Data were collected on 105 children with dehydration due to gastroenteritis who received an ondansetron oral disintegrating formulation. The following outcomes of efficacy were analyzed: number of vomiting episodes, volume of oral rehydration fluids consumed, percent weight gain, and the proportions of children who had ongoing vomiting, received intravenous rehydration, and were hospitalized. In addition, the number of episodes of diarrhea was evaluated to measure whether there were dose-dependent side effects.

Results

Participants were aged 0.5–8.2 years and the dose ranged between 0.13 and 0.26mg/kg. There was no significant association between the dose of ondansetron and the outcomes of number of vomiting episodes, volume of fluids consumed, increase in bodyweight, or number of diarrhea episodes/hour. The mean dose of ondansetron (mg/kg) administered was not different amongst those who did and did not have ongoing vomiting, undergo hospitalization, and receive intravenous rehydration.

Conclusions

Within the dose range of 0.13–0.26 mg/kg, higher doses of ondansetron were not superior to lower doses, nor were they associated with increased side effects. Thus, ondansetron in this dose range was shown to result in a similar reduction in emesis in children with acute gastroenteritis.
Literature
1.
go back to reference Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet 2003; 361: 2226–34PubMedCrossRef Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet 2003; 361: 2226–34PubMedCrossRef
2.
go back to reference King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52: 1–16PubMed King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52: 1–16PubMed
3.
go back to reference Forster J, Guarino A, Parez N, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009; 123: e393–400PubMedCrossRef Forster J, Guarino A, Parez N, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009; 123: e393–400PubMedCrossRef
4.
go back to reference Mast TC, DeMuro-Mercon C, Kelly CM, et al. The impact of rotavirus gastroenteritis on the family. BMC Pediatrics 2009; 9: 11PubMedCrossRef Mast TC, DeMuro-Mercon C, Kelly CM, et al. The impact of rotavirus gastroenteritis on the family. BMC Pediatrics 2009; 9: 11PubMedCrossRef
5.
go back to reference Pascicha PJ. Prokinetic and antiemetic drugs. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 10th ed. Toronto (ON): McGraw-Hill Companies, Inc., 2001: 1029–33 Pascicha PJ. Prokinetic and antiemetic drugs. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 10th ed. Toronto (ON): McGraw-Hill Companies, Inc., 2001: 1029–33
6.
go back to reference Freedman SB, Adler M, Seshadri R, et al. Oral ondansetron for gastroenteritis in a pediatric emergency department. New Engl J Med 2006; 354: 1698–705PubMedCrossRef Freedman SB, Adler M, Seshadri R, et al. Oral ondansetron for gastroenteritis in a pediatric emergency department. New Engl J Med 2006; 354: 1698–705PubMedCrossRef
7.
go back to reference Ramsook C, Sahagun-Carreon I, Kozinetz CA, et al. A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med 2002; 39: 397–403PubMedCrossRef Ramsook C, Sahagun-Carreon I, Kozinetz CA, et al. A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med 2002; 39: 397–403PubMedCrossRef
8.
go back to reference Reeves JJ, Shannon MW, Fleisher GR. Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. Pediatrics 2002; 109: e62PubMedCrossRef Reeves JJ, Shannon MW, Fleisher GR. Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. Pediatrics 2002; 109: e62PubMedCrossRef
9.
go back to reference Roslund G, Hepps TS, McQuillen KK. The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. Ann Emerg Med 2008; 52: 22–9PubMedCrossRef Roslund G, Hepps TS, McQuillen KK. The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. Ann Emerg Med 2008; 52: 22–9PubMedCrossRef
10.
go back to reference Stork CM, Brown KM, Reilly TH, et al. Emergency department treatment of viral gastritis using intravenous ondansetron or dexamethasone in children. Acad Emerg Med 2006; 13: 1027–33PubMedCrossRef Stork CM, Brown KM, Reilly TH, et al. Emergency department treatment of viral gastritis using intravenous ondansetron or dexamethasone in children. Acad Emerg Med 2006; 13: 1027–33PubMedCrossRef
11.
go back to reference Cubeddu LX, Trujillo LM, Talmaciu I, et al. Antiemetic activity of ondansetron in acute gastroenteritis. Aliment Pharmacol Ther 1997; 11: 185–91PubMedCrossRef Cubeddu LX, Trujillo LM, Talmaciu I, et al. Antiemetic activity of ondansetron in acute gastroenteritis. Aliment Pharmacol Ther 1997; 11: 185–91PubMedCrossRef
12.
go back to reference DeCamp LR, Byerley JS, Doshi N, et al. Use of antiemetic agents in acute gastroenteritis: a systematic review and meta-analysis. Arch Pediatr Adolesc Med 2008; 162: 858–65PubMedCrossRef DeCamp LR, Byerley JS, Doshi N, et al. Use of antiemetic agents in acute gastroenteritis: a systematic review and meta-analysis. Arch Pediatr Adolesc Med 2008; 162: 858–65PubMedCrossRef
13.
go back to reference Manteuffel J. Use of antiemetics in children with acute gastroenteritis: are they safe and effective? J Emerg Trauma Shock 2009; 2: 3–5PubMedCrossRef Manteuffel J. Use of antiemetics in children with acute gastroenteritis: are they safe and effective? J Emerg Trauma Shock 2009; 2: 3–5PubMedCrossRef
14.
15.
go back to reference Leung AK, Robson WL. Acute gastroenteritis in children: role of anti-emetic medication for gastroenteritis-related vomiting. Paediatr Drugs 2007; 9: 175–84PubMedCrossRef Leung AK, Robson WL. Acute gastroenteritis in children: role of anti-emetic medication for gastroenteritis-related vomiting. Paediatr Drugs 2007; 9: 175–84PubMedCrossRef
16.
go back to reference Sandoval C, Corbi D, Strobino B, et al. Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. Cancer Invest 1999; 17: 309–13PubMedCrossRef Sandoval C, Corbi D, Strobino B, et al. Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. Cancer Invest 1999; 17: 309–13PubMedCrossRef
17.
go back to reference Lawhorn CD, Kymer PJ, Stewart FC, et al. Ondansetron dose response curve in high-risk pediatric patients. J Clin Anesth 1997; 9: 637–42PubMedCrossRef Lawhorn CD, Kymer PJ, Stewart FC, et al. Ondansetron dose response curve in high-risk pediatric patients. J Clin Anesth 1997; 9: 637–42PubMedCrossRef
18.
go back to reference Sadhasivam S, Shende D, Madan R. Prophylactic ondansetron in prevention of postoperative nausea and vomiting following pediatric strabismus surgery: a dose-response study. Anesthesiology 2000; 92: 1035–42PubMedCrossRef Sadhasivam S, Shende D, Madan R. Prophylactic ondansetron in prevention of postoperative nausea and vomiting following pediatric strabismus surgery: a dose-response study. Anesthesiology 2000; 92: 1035–42PubMedCrossRef
19.
go back to reference Watcha MF, Bras PJ, Cieslak GD, et al. The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery. Anesthesiology 1995; 82: 47–52PubMedCrossRef Watcha MF, Bras PJ, Cieslak GD, et al. The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery. Anesthesiology 1995; 82: 47–52PubMedCrossRef
20.
go back to reference Hasler SB, Hirt A, Ridolfi Luethy A, et al. Safety of ondansetron loading doses in children with cancer. Support Care Cancer 2008; 16: 469–75PubMedCrossRef Hasler SB, Hirt A, Ridolfi Luethy A, et al. Safety of ondansetron loading doses in children with cancer. Support Care Cancer 2008; 16: 469–75PubMedCrossRef
21.
go back to reference Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932–47PubMedCrossRef Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932–47PubMedCrossRef
22.
go back to reference Seynaeve C, Schuller J, Buser K, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis: a multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 1992; 66: 192–7PubMedCrossRef Seynaeve C, Schuller J, Buser K, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis: a multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 1992; 66: 192–7PubMedCrossRef
23.
go back to reference Lajolo PP, del Giglio A. Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials. Support Care Cancer 2007; 15: 343–6PubMedCrossRef Lajolo PP, del Giglio A. Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials. Support Care Cancer 2007; 15: 343–6PubMedCrossRef
Metadata
Title
Ondansetron Dosing in Pediatric Gastroenteritis
A Prospective Cohort, Dose-Response Study
Authors
Stephen B. Freedman
Elizabeth C. Powell
Alejandro A. Nava-Ocampo
Dr Yaron Finkelstein
Publication date
01-12-2010
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 6/2010
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.2165/11537770-000000000-00000

Other articles of this Issue 6/2010

Pediatric Drugs 6/2010 Go to the issue

Announcement

Acknowledgment